See the DrugPatentWatch profile for ruxolitinib

Based on the information available, Ruxolitinib is a medication that is used to treat certain types of myelofibrosis, a bone marrow disorder, and polycythemia vera, a type of blood cancer [1]. According to the Apotex Corp. patent for a formulation that combines Ruxolitinib with other drugs, the other active ingredients in the formulation are not specified in the patent abstract [2].

After conducting further research, I was unable to find any other specific drugs that are combined with Ruxolitinib in Apotex's formulation on DrugPatentWatch.com or any other reputable sources. It is important to note that the specific formulation and combination of drugs in a medication can be subject to change and may vary depending on the specific patent and formulation.

In conclusion, based on the available information, the specific drugs that are combined with Ruxolitinib in Apotex's formulation are not specified in the patent abstract, and I was unable to find any other specific information regarding this formulation.

Sources:

[1] "Ruxolitinib." National Library of Medicine, <https://medlineplus.gov/druginfo/meds/a613042.html>.

[2] "Compositions Comprising Ruxolitinib and Methods of Use Thereof." Google Patents, <https://patents.google.com/patent/US10154026B2/en>.